While I have always liked health-care giant Johnson & Johnson, it's hard to recommend taking a position at these levels.
The stock is already up more than 22 percent on the year and trading at a price/earnings ratio that is more than twice that of rival Abbott Laboratories and eight points higher than Pfizer.